Yamada Yota, Miyazaki Motoyasu, Kushima Hisako, Komiya Yukie, Nakashima Akio, Ishii Hiroshi, Imakyure Osamu
Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka 818-8502, Japan.
Department of Infection Control and Prevention, Fukuoka University Chikushi Hospital, Fukuoka 818-8502, Japan.
Antibiotics (Basel). 2023 Feb 21;12(3):428. doi: 10.3390/antibiotics12030428.
A nucleic acid amplification test (NAAT) is recommended to determine whether or not patients have a infection (CDI) when the glutamate dehydrogenase activity assay is positive and the rapid membrane enzyme immunoassays for toxins is negative. In our hospital, a NAAT was introduced to diagnose CDI precisely in April 2020. This study aimed to investigate the impact of a NAAT on the clinical outcomes in patients with CDI at our hospital. Seventy-one patients diagnosed with CDI between April 2017 and March 2022 were included in our study. Patients with CDI were divided into two groups: before (pre-NAAT) and after (post-NAAT) the introduction of NAAT. The clinical outcome was compared between the two groups. Of the 71 patients with CDI, 41 were sorted into the pre-NAAT group and 30 into the post-NAAT group. The clinical cure rate was significantly higher in the post-NAAT group compared to the pre-NAAT group (76.7% vs. 48.8%, = 0.018). In the multivariable analysis, the clinical cure was significantly associated with the introduction of NAAT ( = 0.022). Our findings suggest that the introduction of NAAT can improve the clinical outcomes in CDI patients.
当谷氨酸脱氢酶活性检测呈阳性且毒素快速膜酶免疫检测呈阴性时，建议进行核酸扩增试验（NAAT）以确定患者是否患有艰难梭菌感染（CDI）。2020年4月，我院引入了NAAT以准确诊断CDI。本研究旨在调查NAAT对我院CDI患者临床结局的影响。2017年4月至2022年3月期间诊断为CDI的71例患者纳入本研究。CDI患者分为两组：NAAT引入前（NAAT前）和引入后（NAAT后）。比较两组的临床结局。在71例CDI患者中，41例被归入NAAT前组，30例被归入NAAT后组。NAAT后组的临床治愈率显著高于NAAT前组（76.7%对48.8%，P = 0.018）。在多变量分析中，临床治愈与NAAT的引入显著相关（P = 0.022）。我们的研究结果表明，NAAT的引入可以改善CDI患者的临床结局。
